Who Generates More Revenue? Takeda Pharmaceutical Company Limited or argenx SE

Takeda vs. argenx: A Revenue Showdown in Pharma

__timestampTakeda Pharmaceutical Company Limitedargenx SE
Wednesday, January 1, 201417778240000004579319.93
Thursday, January 1, 201518073780000007504448.39
Friday, January 1, 2016173205100000015466459
Sunday, January 1, 2017177053100000043793829
Monday, January 1, 2018209722400000024564806
Tuesday, January 1, 2019329118800000078116087
Wednesday, January 1, 2020319781200000044848173
Friday, January 1, 20213569006000000497277000
Saturday, January 1, 20224027478000000410746000
Sunday, January 1, 202342637620000001226316000
Monday, January 1, 20244263762000000
Loading chart...

Unlocking the unknown

Revenue Giants: Takeda vs. argenx

In the ever-evolving pharmaceutical landscape, revenue generation is a key indicator of a company's market position and growth potential. Takeda Pharmaceutical Company Limited, a stalwart in the industry, has consistently outperformed its peers, including argenx SE, a rising star in the biotech sector. From 2014 to 2023, Takeda's revenue surged by approximately 140%, reaching a peak in 2023. In contrast, argenx SE, despite its impressive growth trajectory, saw its revenue increase by over 26,000% during the same period, albeit from a much smaller base. This stark contrast highlights the different scales at which these companies operate. While Takeda's revenue in 2023 was over 3,000 times that of argenx, the latter's rapid growth underscores its potential to disrupt the market. As we look to the future, the absence of 2024 data for argenx leaves room for speculation on its continued ascent.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025